• CRMI posted profit attributable to equity holders of HK$ 4.62 million, little changed from the year-earlier period.
• Revenue rose 52.35% to HK$ 41.73 million, driven by higher spending from Mainland China customers.
• Gross profit climbed 36.02% to HK$ 24.32 million.
• Total operating expenses increased 14.38% to HK$ 20.12 million on higher staff costs and marketing expenses.
• Management flagged uneven recovery in discretionary spending and pressure on Hong Kong demand as more leisure spending shifted to Mainland China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRMI - China Regenerative Medicine International Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294428), on August 21, 2026, and is solely responsible for the information contained therein.